Septerna had its Relative Strength (RS) Rating upgraded from 84 to 92 Tuesday.
IBD's unique RS Rating tracks technical performance by showing how a stock's price action over the last 52 weeks compares to that of the other stocks in our database.
History shows that the market's biggest winners often have an RS Rating of over 80 in the early stages of their moves.
How To Use Stock Charts To Stay Profitable And Protected
Now is not an ideal time to jump in since it isn't near a proper buy zone, but see if the stock manages to offer and clear a proper buy point.
Septerna posted 0% EPS growth in the latest quarterly report. Sales rose 500%.
The company earns the No. 75 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals, ADMA Biologics and Exelixis are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
